CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“Gene therapy is in the midst of renaissance, and Dimension Therapeutics is poised to stand out among a new generation of biotech startups,” says Damian Garde, editor of FierceBiotech. “Matching REGENX’s pioneering technology with CEO Annalisa Jenkins’ Big Pharma R&D expertise and the support of some banner investors, the company is moving swiftly with some promising treatments for genetic disorders.”
Dimension is focused on advancing its platform of gene therapy programs in rare diseases, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. The company is a leader in AAV gene therapy with preferred access to key IP and technology through its collaboration with REGENX Biosciences, world-class development capabilities, and a strong team of experts in the areas of rare disease, gene therapy and drug development.
“Dimension is honored to be recognized in the Fierce 15 class of 2014 for our leadership in advancing AAV gene therapies for rare diseases,” said Annalisa Jenkins, MBBS, MRCP, chief executive officer of Dimension Therapeutics. “This award adds to the strong momentum Dimension has experienced since launch, including our hemophilia A partnership with Bayer, which is the largest single target adeno-associated virus gene therapy collaboration to date, and the $30 million series A round from investors Fidelity Biosciences and OrbiMed. We are strongly positioned to continue progressing our robust pipeline in both hemophilia and other rare diseases, with the goal of developing therapies that provide long-term, sustainable benefits and meaningfully impact the lives of patients.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. This is FierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.
About Dimension Therapeutics
Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Formed in 2013 by REGENX Biosciences and Fidelity Biosciences, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic capabilities and advancing multiple gene therapy programs in rare diseases, including a hemophilia A program through its collaboration with Bayer HealthCare, and a wholly-owned hemophilia B program, towards clinical development. Dimension has exclusive gene therapy intellectual property and preferred access to multiple best-in-class AAV vectors based on REGENX’s NAV® technology. Dimension is backed by leading investors Fidelity Biosciences and OrbiMed. For more information, please visit www.dimensiontx.com.